Valeant Pharmaceuticals And EyeGate Enter Into Licensing Agreement For EGP-437 Combination Product In Post-Operative Pain And Inflammation In Ocular Surgery Patients

Novel Approach Offers Eye Care Practitioners Delivery Alternative for Post-Operative Therapeutic Regimens 
 
LAVAL, Quebec and WALTHAM, Mass., Feb. 21, 2017 -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") and EyeGate Pharmaceuticals, Inc. (Nasdaq: EYEG) ("EyeGate"), a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of the eye, today announced that they have entered into an exclusive, worldwide licensing agreement through which EyeGate has granted a subsidiary of Valeant exclusive, worldwide commercial and manufacturing rights to the EyeGate® II Delivery System and EGP-437 combination product candidate for the treatment of post-operative pain and inflammation in ocular surgery patients.
Published: 21 February 2017
Written by Editor
Nasdaq   New Product or Order   Up on News  
Read more: EyeGate Pharmaceuticals Inc ( EYEG )

Immune Pharmaceuticals Announces the launch of REMAIN ™ , an international Overall Survival study with Ceplene ® and low dose Proleukin ® in REmission MAINtenance in Acute Myeloid Leukemia

Ceplene Currently Approved in Europe and Israel
REMAIN™ to be a pivotal study for US approval
 
NEW YORK, Feb. 17, 2017  -- Immune Pharmaceuticals Inc. (Nasdaq: IMNP), will announce on Monday, February 20th, 2017 at the Acute Leukemia XVI symposium in Munich, Germany that it will be launching REMAIN™, an international Overall Survival clinical study with the combination of Ceplene®, the Company's flagship product for Acute Myeloid Leukemia (AML) remission maintenance and relapse prevention, and low dose Proleukin®. Patient recruitment is expected to start in later 2017.
Published: 17 February 2017
Written by Editor
Nasdaq   Up on News   Project Update  
Read more: Immune Pharmaceuticals( IMNP )

Cannabix Technologies Provides Update on Marijuana Breathalyzer Development

The Cannabix Marijuana Breathalyzer is being developed to give law enforcement and employers a tool to enforce public safety as Canada gets set to table marijuana legalization this spring
 
VANCOUVER, BRITISH COLUMBIA--( Feb. 16, 2017) - Cannabix Technologies Inc. (CSE:BLO)(CSE:BLO.CN)(OTC PINK:BLOZF) (the "Company or Cannabix") developer of the Cannabix Marijuana Breathalyzer for law enforcement and the workplace, is pleased to provide a development update on its FAIMS Beta 2.0 (field asymmetric waveform ion mobility spectrometry) based marijuana breathalyzer for the detection of ∆9-tetrahydrocannabinol ("THC") in human breath. Development in Gainesville, Florida and Vancouver, BC is progressing well and the Company expects to begin pre-trial live subject testing during the month of March.
Published: 16 February 2017
Written by Editor
Up on News   Project Update   TSXV  
Read more: Cannabix Technologies ( BLO )

Revive Therapeutics Announces Expansion into Cannabinoid-Based Therapies Targeting Liver Diseases

TORONTO, ONTARIO--(Feb. 16, 2017) - Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE:RVV) (OTCQB:RVVTF), a company focused on the research, development and commercialization of novel treatments for serious and unmet medical needs, today announced the Company is expanding its product pipeline through the development of cannabinoid-based therapeutics targeting liver diseases.
 
"Through our dedicated bioinformatics platform specifically designed to identify repurposed and innovative drug and plant-based treatments, such as cannabinoids, and with consultation of our experts in cannabinoid research, we have identified potential cannabinoid-based lead opportunities in a number of liver diseases," said Craig Leon, Chief Executive Officer of Revive. "We expect these initiatives to progress in the near-term and we will update the medical and investment communities as they occur."
Published: 16 February 2017
Written by Editor
Up on News   Project Update   TSXV  
Read more: Revive Therapeutics ( RVV )

Neuralstem Announces Last Subject Enrolled in Phase 2 Trial with NSI-189 for Major Depressive Disorder

- Phase 2 Data Now Expected Ahead of Schedule in 3Q 2017 -
 
GERMANTOWN, Md., Feb. 16, 2017  -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, today announced completion of subject enrollment in its Phase 2 clinical trial of NSI-189 for the treatment of major depressive disorder (MDD).  NSI-189 is a new chemical entity and the lead compound in Neuralstem's neurogenic small molecule program.  Enrollment was completed ahead of schedule and data are expected in 3Q 2017.
 
“Completing the last subject enrolled in the Phase 2 study with NSI-189 for the treatment of MDD earlier than expected is a significant clinical development milestone for Neuralstem,” said Rich Daly, Chairman and CEO, Neuralstem.  “We now expect results from the Phase 2 study in the 3Q of 2017, and results from the subsequent, 6-month observational study to assess NSI-189’s durability effect will be available in the first half of 2018. We are thankful to the individuals and physicians who are participating in these studies and helping us to move closer to potentially bringing this new category of treatment forward.”
Published: 16 February 2017
Written by Editor
Nasdaq   Up on News   Project Update  
Read more: Neuralstem Inc ( CUR )
  1. Sage Therapeutics ( SAGE )
  2. Zosano Pharma Corporation ( ZSAN )
  3. Immunomedics Inc ( IMMU )
  4. Pulse Biosciences Inc ( PLSE )
  5. Acorda Therapeutics Inc ( ACOR )